title: Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?
abstract: Nonalcoholic fatty liver disease (NAFLD), which spans a spectrum of conditions ranging from simple steatosis to progressive nonalcoholic steatohepatitis (NASH), is the most common chronic liver disease and a relevant public health issue. The prevalence of NAFLD depends on adiposity, age, gender and ethnicity. The natural history of liver disease in those with NAFLD critically depends on liver histological changes. However, cardiovascular mortality is increased in NAFLD, particularly in middle-aged adults. Against such a background, this review consists of three sections. First, data on NAFLD as a novel mechanism of increased cardiovascular risk via hyperinsulinism, pro-thrombotic potential, and subclinical inflammation are summarized. Next, the role of atherogenic liver in the development of manifestations of oxidative stress and atherosclerosis is emphasized. Finally, whether and how treating NAFLD will mechanistically result in reduced cardiovascular risk through ameliorated metabolic syndrome is discussed.
authors.affiliation: Department of Internal Medicine, Endocrinology, Metabolism and Geriatrics, Nuovo Ospedale Civile Sant'Agostino-Estense di Modena, University of Modena and Reggio Emilia, Modena, Italy. m.maurantonio@ausl.mo.it
authors.forename: Mauro
authors.initials: M
authors.lastname: Maurantonio
authors.forename: Stefano
authors.initials: S
authors.lastname: Ballestri
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Odoardi
authors.forename: Amedeo
authors.initials: A
authors.lastname: Lonardo
authors.forename: Paola
authors.initials: P
authors.lastname: Loria
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D005234:Fatty Liver / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D040242:Risk Reduction Behavior